USNA auf dem Weg zu 500% dieses Jahr.
ist aber in meinem Thread "Die besten Aktien weltweit" untergegangen.
Usana konnte Anfang des Jahres mit sehr guten Quartalszahlen aufwarten, hatte ich auch vorgestellt, jetzt kommen morgen die neuen Zahlen und die sind wieder gut, der Gewinn wurde verdreifacht zum Vorjahresquartal.
Der erstaunt es nicht, dass Usana die vorbörslich stärkste Aktie an der Nasdaq
ist.
Zahlen werden morgen veröffentlicht:
USANA 3rd Quarter EPS 22 Cents
Usana Health Sciences Inc. - Salt Lake City
3rd Quar Sept. 28:
2002 2001
Sales $34,787,000 $29,341,000
Net income 2,343,000 586,000
Avg shrs 10,608,000 9,708,000
Shr earns
Net income .22 .06
Morgen fallen die Nasdaq und die deutschen Börsen, Intel hat enttäuscht, daß
strahlt erstmal aus. Intel ist vorbörslich 13% im Minus.
Aber Usana ist der Hammer. ( Hab se leider letzte Woche verkauft, vor den Zahlen verkaufe ich immer. ) Wenn die Zahlen nämlich schlecht sind, kann es
ne böse Überraschung geben, wenn die Zahlen gut sind kann man getrost zu höheren Kursen weiterkaufen.
Aber zurück zu Usana: Morgen fallen die 8 Euro endlich und ein neues Kaufsignal wird generiert mit Ziel ??? 12 Dollar könnten durchaus noch drin sitzen dieses Jahr.
52-weeks low bei 0,18, akt bei 3,63
EVOLVING SYSTEMS INC - Nasdaq SmallCap Market: EVOL
Consolidated Real-time Market Quote*
| Last | Change (%) | After Hours Chg (%)** | Bid | Ask | Trade Time |
| -- | -- |  0.279 (7.69) | 0 (0) | 0 (0) | -- |
Exchange Quote
| Last | Change (%) | Bid (size) | Ask (size) | Trade Time |
| 3.63 | 0.23 (6.76) | 0.01 (1) | 4.76 (20) | 15:59 |
| Day Volume | Last Size | Open | High | Low |
| 0 | 100 | 3.55 | 3.72 | 3.40 |
| Latest Ticks | # of Trades | Avg Trade Size | 52 Wk High | 52 Wk Low |
| --== | 271 | 0 | 3.65 | 0.18 |
| Prev Close | Avg Day Vol | |||
| 3.40 | 182,900 |
Überwiegend arbeiten wir (schau mal in den US-Depotwettbewerb hier im Board) viel mit dem Internet. Da steckt richtig Arbeit dahinter, News suchen, Zahlen bewerten, Charts analysieren...
Hoffe ich konnte Dir ein wenig weiterhelfen.
Beste Grüße
Pavian
Legen nachbörslich über 2$ zu.
Bis zum Wochenende, zur Tradingrunde.
Gruss E.
| GENAISSANCE PHARMA INC |  |
| You can't navigate in the Quotes & Research area without a Javascript-enabled browser. | ||||||
| Enter symbol(s): Don't know the symbol? - 0){tmp+=sym.substring(0,x)+s; sym=sym.substring(x+1)}; return tmp+sym}; var tickers=document.symbol_entry.p.value; tickers=subst(tickers,'+','%2B'); tickers=subst(tickers,' ','%20'); tickers=subst(tickers,',','%2C'); location.href='/investments/portfolio/AddToPort/?AddToPortfolio=1&p='+tickers+'&ref=quotes&channel=investments'}">Add to your watchlist - Printer-friendly version |
| |||||
| GNSC |
| Last Trade | 2.48 | Volume | 248,725 | |||
| Change | +0.38 | Avg Volume | 121,496 | |||
| Bid / Ask | 2.32 / 2.40 | Mkt Cap (mil) | $57.14 | |||
| Open | 2.11 | P/E | N/E* | |||
| Prev Close | 2.10 | Div Yield | N/A | |||
| Day's Range | 2.07 - 2.50 | Annual Div/Sh | None | |||
| 52-wk Range | 0.37 - 2.26 | Market | NASDAQ | |||
| ||||||
| *N/E - No Earnings |
| Thursday, October 02, 2003 03:58 PM EDT. Quote delayed: 15 minutes Nasdaq, 20 minutes others. |
| Recent Headlines |
(Adds details, outlook, stock activity)
PALO ALTO, Calif., Oct 14 (Reuters) - USANA Health Sciences Inc. on Tuesday posted higher third-quarter earnings, raised its forecast for the fourth quarter and announced a stock split.
The company Salt Lake City-based maker of nutritional, personal care and weight management products, said its board approved a 2-for-1 stock split.
USANA shares, which had closed at $54.74 on the Nasdaq, were up 4 percent to $57 in extended trade on Instinet.
For its fiscal third quarter ended Sept. 27, USANA said net earnings rose to $6.1 million, or 57 cents per diluted share, from $2.3 million, or 22 cents per diluted share in the year ago period. Net sales grew to $52.5 million from $34.8 million a year ago.
The company attributed the increase in earnings to positive exchange rates and the opening of the South Korean market.
USANA said it bumped up guidance based on the third-quarter's results, forecasting fourth-quarter net sales approaching $57 million and earnings in the range of 57 cents to 59 cents a share, on a pre-split basis.
For 2004, USANA forecast sales of $240 million to $250 million and earnings of $2.45 per share to $2.55 per share, on a pre-split basis.
The company said the stock split will be effected by means of a stock dividend and will double the number of outstanding shares to about 19,050,000. Dividend shares will be distributed on or about Oct. 30, to stockholders of record as of Oct. 24, 2003.
((Reporting by Lisa Baertlein; Reuters Messaging: lisa.baertlein.reuters.com@reuters.net; 650-461-3401; Editing by Carol Bishopric))
For Related News, Double Click on one of these codes:
[E] [U] [RNP] [DNP] [PCO] [CRD] [PCU] [DRU] [US] [ISU] [RES] [RESF] [LEN] [RTRS] [USNA.O]
For Relevant Price Information, Double Click on one of these codes:
Tuesday, 14 October 2003 23:28:24
RTRS [nN14183872] {EN}
ENDS
Gruss E.
Genaissance Pharmaceuticals Secures $11.1 Million in Funding - Financing Package Could Total $15.4 Million -
NEW HAVEN, Conn., Oct 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- Genaissance
Pharmaceuticals, Inc. (Nasdaq: GNSC) today announced that it has secured $11.1
million from two transactions with a potential for an additional investment of
$4.3 million.
RAM Trading, Ltd. ("RAM"), an affiliate of an existing investor, purchased
270,000 shares of newly-designated Series A Preferred Stock at a price of $22.50
per share, totaling approximately $6.1 million. The proceeds from the
transaction will be used for working capital and general corporate purposes.
These shares can be converted by RAM at any time into 2.7 million shares of
common stock. The preferred stock pays an annual cash dividend of 2%.
Genaissance also issued a warrant to RAM exercisable for an additional 190,000
shares of Series A Preferred Stock under the same terms until December 31, 2005.
If Genaissance's common stock price is above $4.00 for 23 consecutive business
days, RAM would be required to purchase the additional shares at a specified
time. If Genaissance sells the additional 190,000 shares, RAM's investment would
total approximately $10.4 million. In addition, Genaissance granted RAM certain
other rights, including registration rights and certain put rights that can be
exercised beginning on the third anniversary of the closing of the transaction.
Genaissance also announced that on September 30, 2003, it signed a three-year,
$5.0 million term loan with Comerica Bank. The funds from this loan were
primarily used to help repay all existing capital leases, substantially reducing
Genaissance's annual principal and interest payments.
"This funding completes the restructuring plan for our balance sheet, which we
began last year, and further helps position us financially to execute our
business plan of building the preeminent Pharmacogenetics company," said Kevin
Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "We
are extremely pleased by the additional support from an affiliate of one of our
significant shareholders, which we believe is a tangible expression of
confidence in our business."
Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of
human gene variation for the development of a new generation of DNA-based
diagnostic and therapeutic products. Genaissance markets its technology,
clinical development skills and pharmacogenetic services to the pharmaceutical
industry as a complete solution for improving the development, marketing and
prescribing of drugs. Genaissance has agreements with major pharmaceutical,
diagnostic and biotechnology companies. Genaissance is headquartered in Science
Park in New Haven, Connecticut. Visit the company's website at
www.genaissance.com.
This press release contains forward-looking statements, including statements
about the receipt of additional proceeds from the sale of Series A Preferred
Stock and our expected financial position. Such statements are subject to
certain factors, risks and uncertainties that may cause actual results, events
and performance to differ materially from those referred to in such statements,
including, but not limited to, the trading price of our common stock, our
expected cash proceeds, the attraction of new business and strategic partners,
the adoption of our technologies by the pharmaceutical industry, the timing and
success of clinical trials, competition from pharmaceutical, biotechnology and
diagnostics companies, the strength of our intellectual property rights, and
those risks identified in our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 14, 2003, and in other filings we
make with the Securities and Exchange Commission from time to time. The
forward-looking statements contained herein represent the judgment of
Genaissance as of the date of this release. Genaissance disclaims any obligation
to update any forward-looking statement.
SOURCE Genaissance Pharmaceuticals, Inc.
Die "Mad Cows" waren ein Geschenk gratis für EDET.
Auf baldige Zweiarmigkeit. ( ENCY fast durch die 10, alter Freak )
Gruss E.
Fans of Atkins(R) Find Non-Beef Alternatives at eDiets.com(TM)
TUESDAY, DECEMBER 30, 2003 4:20 PM
- PR Newswire
EDET
6.16 +0.11
DEERFIELD BEACH, Fla., Dec 30, 2003 /PRNewswire-FirstCall via Comtex/ -- Followers of the Atkins Nutritional Approach(R) have plenty of non-beef options to choose from at eDiets.com, a leading online diet destination for consumers seeking personalized advice, nutrition information, products and services. eDiets.com makes it possible to adhere to the low-carbohydrate philosophy espoused by the Atkins Nutritional Approach.
"When it comes to dieting, we all know how easy it is to fall off the wagon," said Susan Burke, Director of Nutrition Services at eDiets.com. "If you're concerned about eating beef right now, our flexible meal plans allow you to exclude beef, and include chicken, fish and pork, if you choose. All meals have exactly the elements every Atkins Nutritional Approach meal should have."
The long list of non-beef options available from Atkins Nutritional Approach at eDiets.com include roast chicken with baked Brie and sun-dried tomatoes, salsa fish with salad, shrimp and broccoli stir-fry, an open-face roast pork sandwich on Atkins bread, and roast chicken almond salad. Consumers have a wide range of choices with Atkins. For more information on these and other alternatives, go to www.eDiets.com.
eDiets.com has enjoyed significant success with its personalized version of the Atkins Nutritional Approach, which includes customized meal plans catering to individual needs and preferences, daily menus, shopping lists and 24/7 online support. The Atkins plan has been available at www.eDiets.com since April 2003, and has already become one of eDiets most popular options.
eDiets.com has translated Atkins' four-phase program that starts by limiting refined carbohydrates from sugar and refined flour products, and includes liberal portions of protein and healthy fats. As members progress toward their goal weight, the program adds back graduated portions of healthy carbs, including fruits and vegetables, grains, nuts and dairy.
About eDiets.com
eDiets.com is the premier online "diet destination" for consumers seeking professional advice, information, products and services that challenge overweight individuals both domestically and abroad to get in shape to live longer. Over 1.3 million consumers worldwide have become eDiets.com members since its inception in 1996.
eDiets.com offers 15 personalized programs including the Atkins Nutritional Approach(R), the Zone Diet(TM), Shape Up!(TM) inspired by Dr. Phil McGraw's Ultimate Weight Solution, the eDiets.com Alternative to Jenny Craig, and more than a dozen specialized healthy living programs for those with special needs, including Type 2 Diabetes, Heart Smart and The Vegetarian Diet.
Members choose a plan and complete a personal profile questionnaire to determine how to best custom tailor the program for their unique needs. Each meal plan is personalized for the member's food preferences and lifestyle, and custom shopping lists are provided that allow members to buy everything for the plan at the supermarket. To ensure success, members have 24/7/365 access to eDiets.com's "Support Central" through which they can garner real-time motivation and support from eDiets.com's on-staff experts and member peers. An eDiets.com nutrition program costs $5 per week, and members can change among available plans at their discretion at no additional charge; personalized fitness costs an additional $1 per week.
Dieting is a $30 billion market with established brands such as Jenny Craig(R), Weight Watchers(R) and several regional brands. Founded in 1996, eDiets.com is a public company (EDET) headquartered in Deerfield Beach, FL. that operates Web sites at www.eDiets.com and www.eFitness.com, as well as www.eDietsuk.co.uk in Ireland and the United Kingdom and www.eDiets.de in Germany.
CORPORATE CONTACT: MEDIA CONTACT:
Merilee Kern, Eric Goldman, Neale-May & Partners
Manager Marketing Communications Vice President
954-360-9022 212-213-5400x202
merilee@eDiets.com egoldman@nealemay.com
SOURCE eDiets.com
Corporate - Merilee Kern, Manager Marketing Communications of
eDiets.com, +1-954-360-9022, merilee@eDiets.com; or Media - Eric Goldman, Vice
President of Neale-May & Partners, +1-212-213-5400, ext. 202,
egoldman@nealemay.com, for eDiets.com
http://www.prnewswire.com
NEW HAVEN, Conn., Jan 09, 2004 /PRNewswire-FirstCall via Comtex/ -- Genaissance
Pharmaceuticals, Inc. (Nasdaq: GNSC) announced today that it had completed an
analysis of DNA samples for the United States Department of Agriculture (USDA)
as part of the USDA's effort to trace the origin of the animal infected with
bovine spongiform encephalopathy or Mad Cow disease.
"We were honored that the USDA asked us to analyze these very important
samples," said Gerald F. Vovis, Ph.D., Executive Vice President and Chief
Technology Officer of Genaissance Pharmaceuticals. "We had our personnel
standing by to receive the samples when they arrived by courier and then worked
around the clock to ensure that the results were available as rapidly as
possible."
"We see the use of DNA testing for animal identity and traceability as a new
market opportunity for us and another step in the execution of our strategy to
build a profitable base services business while developing proprietary products
based on our HAP(TM) Technology," Dr. Vovis continued. "We believe that we have
the experience to be a major player in this arena because we have an accredited
genotyping laboratory that has a high-throughput process for analyzing DNA,
including a proprietary laboratory information management system, the necessary
robotics and microarray instrumentation. During the past year, we used this
platform to generate over 8,000,000 DNA analysis results for our customers."
Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of
human gene variation for the development of a new generation of DNA-based
diagnostic and therapeutic products. Genaissance markets its technology,
clinical development skills and pharmacogenomic services to the pharmaceutical
industry as a complete solution for improving the development, marketing and
prescribing of drugs. Genaissance has agreements with major pharmaceutical,
diagnostic and biotechnology companies. Genaissance is headquartered in Science
Park in New Haven, Connecticut. Visit the company's website at
www.genaissance.com.
This press release contains forward-looking statements, including statements
about the expected growth and development of Genaissance's business and market
opportunities, the ability of Genaissance to apply its technologies to the
development, marketing and prescribing of drugs and to detect associations
between clinical outcomes and genetic variation. Such statements are subject to
certain factors, risks and uncertainties that may cause actual results, events
and performance to differ materially from those referred to in such statements,
including, but not limited to, the extent to which genetic markers (haplotypes)
are predictive of clinical outcomes and drug efficacy and safety, the attraction
of new business and strategic partners, the adoption of our technologies by the
pharmaceutical industry, the timing and success of clinical trials, competition
from pharmaceutical, biotechnology and diagnostics companies, the strength of
our intellectual property rights and those risks identified in our Quarterly
Report on Form 10-Q filed with the Securities and Exchange Commission on
November 14, 2003, and in other filings we make with the Securities and Exchange
Commission from time to time. The forward-looking statements contained herein
represent the judgment of Genaissance as of the date of this release.
Genaissance disclaims any obligation to update any forward-looking statement.
SOURCE Genaissance Pharmaceuticals, Inc.
Gruss E.
Genaissance Pharmaceuticals, Inc. to Acquire Lark Technologies, Inc. - Acquisition Complements Genaissance's Pharmacogenomic Base Business - - Significantly Increases Revenues; Adds Profitable Operation and UK Facility -
NEW HAVEN, Conn., and HOUSTON, Dec 19, 2003 /PRNewswire-FirstCall via Comtex/
-- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) and Lark Technologies, Inc (OTC Bulletin Board: LRKT) today announced that they have signed a definitive
agreement whereby Genaissance will acquire Lark in an all stock transaction.
Under the terms of the agreement, Genaissance will issue approximately 6.7
million shares of its common stock to Lark's stockholders, who will receive 1.81
shares of Genaissance's common stock for each share of Lark's common stock that
they own, and will assume outstanding Lark options exercisable for an aggregate
of approximately 1.5 million shares of Genaissance common stock. The transaction
is valued at approximately $19.9 million, based on the closing price of
Genaissance's common stock of $2.99 per share on December 18, 2003.
Following the transaction, Genaissance expects to have projected pro-forma
revenues in excess of $25 million for calendar 2004, a substantially reduced
operating loss, an expanded pharmacogenomic service and technology portfolio
with facilities in the U.S. and England and additional financial resources to
advance the development of pharmacogenomic based proprietary products. Dr. Carl
Balezentis, President and Chief Executive Officer of Lark, will join Genaissance
as Senior Vice President and President, Lark Technologies.
Lark, headquartered in Houston, Texas, with European operations located near
Cambridge, England, offers Good Laboratory Practices (GLP) compliant and
research genomic services for use in pharmaceutical, diagnostic and agricultural
product research and development. For the nine months ended September 30, 2003,
Lark reported revenues of $6.8 million, net income of $1.2 million and operating
income of $1.6 million.
"The acquisition of Lark is an exciting next step in the execution of our
strategy to build a profitable base services business while developing
proprietary products based on our HAP(TM) Technology," said Kevin Rakin,
President and Chief Executive Officer of Genaissance Pharmaceuticals. "The
addition of Lark will provide us with access to a broader client base, a GLP
sequencing capability that complements our existing GLP genotyping ability, a
strong and growing European operation and an experienced team focused on
profitable revenue generation. Most importantly, as we look forward, a
profitable base services business will generate additional funds for the
development of proprietary diagnostic and pharmaceutical products. I am also
very pleased to welcome Dr. Carl Balezentis and his team to Genaissance."
The transaction has been approved unanimously by both Boards of Directors and is
subject to shareholder approval by both companies and other customary closing
conditions. The transaction is expected to close in the first half of 2004. The
dates of special stockholder meetings for shareholders of Lark and Genaissance
will be announced at a later date.
"The combined company's capabilities will provide the pharmaceutical industry a
pharmacogenomic solution spanning early stage research through clinical
development and commercialization," said Carl W. Balezentis, Ph.D., President
and Chief Executive Officer of Lark Technologies. "By becoming part of
Genaissance, we expect to grow significantly our combined business through
additional product offerings, cross selling of services and technologies and the
ability to partner on specific product development opportunities. We are
especially excited about the existing and potential programs for product
development at Genaissance and the value that our shareholders may derive by
participating in the further development and commercialization of these
pharmacogenomic product programs."
Legg Mason Wood Walker, Incorporated and EMA Partners, LLC served as financial
advisors to Genaissance in the transaction and Southwest Securities, Inc. served
as financial advisor to Lark Technologies.
About Lark Technologies